Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
Status:
Completed
Trial end date:
2019-06-27
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC)
OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects
with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or
treated with a stable dose of metformin.
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc. OPKO Ireland Global Holdings Ltd.